Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis

British Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2010, Pages 118-125

  Munson, Jeffrey C ^a,b   Kreider, Maryl ^a   Chen, Zhen ^c   Christie, Jason D ^a,b   Kimmel, Stephen E ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Corticosteroids; Idiopathic pulmonary fibrosis; Pharmacoepidemiology; Treatment guidelines

Indexed keywords

CORTICOSTEROID; CYTOTOXIC AGENT;

AGED; ARTICLE; DATA BASE; DEMOGRAPHY; DRUG USE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 77953529028     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03670.x     Document Type: Article

References (28)

1. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006 61 : 980 985.
2. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003 3 CD002880.
3. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991 144 : 291 296.
4. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005 353 : 2229 2242.
5. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003 3 CD003134.
6. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989 44 : 280 288.
7. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004 350 : 125 133. (Pubitemid 38056223)
8. Fiorucci E, Lucantoni G, Paone G, Zotti M, Li BE, Serpilli M, Regimenti P, Cammarella I, Puglisi G, Schmid G. Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008 12 : 105 111.
9. British Thoracic Society Standards of Care Committee. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. British Thoracic Society and Standards of Care Committee. Thorax 1999 54 (Suppl 1 S1 30.
10. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000 161 : 646 664.
11. Collard HR, Loyd JE, King TE Jr., Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med 2007 101 : 2011 2016.
12. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002 41 : 676 679.
13. Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997 52 : 38 44.
14. Munson JC, Kreider ME, Chen Z, Christie JD, Kimmel SE. Use of corticosteroids and corticosteroid-sparing agents in the initial management of idiopathic pulmonary fibrosis Abstract Chest Meeting Abstracts 2008 134 : S20002.
15. Munson JC, Kreider ME, Christie JD, Kimmel SE. The effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis Abstract Pharmacoepidemiol Drug Saf 2009 18 : S144 5.
16. Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, Britton J. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 2005 14 : 416 421.
17. Kell P, Hvidsten K, Morant S, Harnett J, Bridge S. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. Br J Urol 2007 99 : 860 863.
18. Mortimer KJ, Tata LJ, Smith CJ, West J, Harrison TW, Tattersfield AE, Hubbard RB. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006 61 : 405 408.
19. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006 367 : 1075 1079.
20. Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009 103 : 927 931.
21. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000 161 : 5 8.
22. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005 14 : 443 451.
23. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993 138 : 923 936.
24. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee Thoracic Society of Australia New Zealand Thoracic Society Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008 63 : Suppl. V v1 58.
25. Flaherty KR, Toews GB, Lynch JP 3rd., Kazerooni EA, Gross BH, Strawderman RL, Hariharan K, Flint A, Martinez FJ. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001 110 : 278 282.
26. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 165 : 277 304.
27. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998 157 : 1301 1315.
28. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008 178 : 1257 1261.